Compare · IBB vs VTA
IBB vs VTA
Side-by-side comparison of iShares Nasdaq Biotechnology Index Fund (IBB) and Invesco Credit Opportunities Fund (VTA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IBB and VTA operate in n/a (n/a), so they compete in similar markets.
- VTA carries a market cap of $721.1M.
iShares Nasdaq Biotechnology Index Fund
The investment seeks to track the investment results of the ICE Biotechnology Index composed of U.S.-listed equities in the biotechnology sector. The fund generally will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
Invesco Credit Opportunities Fund
Invesco Dynamic Credit Opportunities Fund is a close-ended fixed income mutual fund launched by Invesco Ltd. The fund is co-managed by Invesco Advisers, Inc., Invesco Asset Management Deutschland GmbH, Invesco Asset Management Limited, Invesco Asset Management (Japan) Limited, Invesco Hong Kong Limited, Invesco Senior Secured Management, Inc., and Invesco Canada Ltd. It invests in the fixed income markets across the globe with a focus on the United States. The fund invests in securities of companies that operate across diversified sectors. It invests in fixed income securities such as senior secured floating rate loans, fixed rate loans, and collateralized debt. The fund employs fundamental analysis with a bottom-up security selection process to create its portfolio. It conducts in-house research to make its investments. The fund benchmarks the performance of its portfolio against the Credit Suisse Leveraged Loan Index. It was formerly known as Invesco Van Kampen Dynamic Credit Opportunities Fund. Invesco Dynamic Credit Opportunities Fund was formed on June 26, 2007 and is domiciled in the United States.
Latest IBB
- Altimmune Added to Nasdaq Biotechnology Index
- Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows
- Stocks Stalls As Chip Sector Struggles To Rebound; Dollar Eyes 7-Week Peak, Gold, Bitcoin Retreat: What's Driving Markets Friday?
- April Showers On Wall Street: Miners, Utilities Emerge As Bright Spots In Gloomy Market
- AI, Biotech, Energy Sectors Expect M&A Revival For 2024
- Live On CNBC, Jason Snipe's Contrarian Idea: Biotech; Names IShares Biotechnology ETF
- US Stocks Eye 3-Day Slump; Tech, Crypto Sell-Off Deepens, Oil, Dollar Rebound: What's Driving Markets Wednesday?
- Tech Drags On Wall Street As 2024 Kicks Off; Dollar and Treasury Yields Surge: What's Driving Markets Tuesday?
- Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback
- Wall Street Sees Post-Holiday Gains, Oil Rallies, Intel Leads: What's Driving Markets Tuesday?
Latest VTA
- SEC Form SC 13G/A filed by Invesco Credit Opportunities Fund (Amendment)
- SEC Form N-CSRS filed by Invesco Credit Opportunities Fund
- SEC Form 425 filed by Invesco Credit Opportunities Fund
- Invesco Advisers Announces Completion of Reorganization of Invesco Dynamic Credit Opportunities Fund into Closed-End Interval Fund
- SEC Form 25-NSE filed by Invesco Credit Opportunities Fund
- SEC Form 425 filed by Invesco Credit Opportunities Fund
- Invesco Advisers Announces Payment of Dividend, Date of Upcoming Reorganization, Date of Ceasing of Trading and Related Matters for Invesco Dynamic Credit Opportunities Fund
- SEC Form SC 13G filed by Invesco Credit Opportunities Fund
- SEC Form 4: Saba Capital Management, L.P. returned $47,662,438 worth of shares to the company (3,893,990 units at $12.24)
- SEC Form 425 filed by Invesco Credit Opportunities Fund